- Home
- BEAT vs AIDX Comparison
BEAT vs AIDX Comparison
Compare BEAT & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BEAT | AIDX |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | 16 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Precision Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.2M | 58.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BEAT | AIDX |
|---|---|---|
| Price | $1.16 | $1.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.75 | N/A |
| AVG Volume (30 Days) | ★ 827.3K | 252.1K |
| Earning Date | 03-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $260.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $1.51 |
| 52 Week High | $4.00 | $14.09 |
Technical Indicators
Market Signals| Indicator | BEAT | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 36.54 | 8.31 |
| Support Level | $0.91 | N/A |
| Resistance Level | $1.35 | $3.08 |
| Average True Range (ATR) | 0.09 | 0.32 |
| MACD | -0.01 | 0.14 |
| Stochastic Oscillator | 16.47 | 10.17 |
Price Performance
Historical ComparisonAbout BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
About AIDX 20/20 Biolabs Inc. Common Stock
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.